Clinical Trials
62 trialsNCT00877500 2026-05-22
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00977574 2026-04-29
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04796324 2026-03-12
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Phase 2 Terminated
NCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
NCT00879086 2023-06-22
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT02067416 2023-02-02
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT01446016 2023-01-23
CAT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00828308 2022-03-08
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Brown University
Phase 2 Completed
NCT00741988 2021-12-15
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00866905 2021-11-22
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01097642 2021-09-22
ICE
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00723957 2020-10-28
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
R-Pharm
Phase 2 Completed
NCT00983801 2020-10-28
Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
R-Pharm
Phase 2 Completed
NCT01818999 2020-08-20
Ixabepilone and SBRT For Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT00924066 2019-11-21
Ixabepilone to Treat Cervical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01416389 2019-09-18
A Study of LY2523355 in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01168232 2019-08-08
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025155 2019-07-24
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00095979 2019-07-24
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00672009 2018-10-24
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT00030706 2018-09-28
Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Montefiore Medical Center
Phase 2 Completed
NCT00627978 2018-06-26
Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
Weill Medical College of Cornell University
Phase 2 Completed
NCT00923130 2018-04-17
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00058084 2017-02-23
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00080262 2017-01-30
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
R-Pharm
Phase 2 Completed
NCT01019577 2017-01-30
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
R-Pharm
Phase 2 Completed
NCT01027208 2017-01-30
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
R-Pharm
Phase 2 Completed
NCT01075100 2016-12-07
Ixabepilone + Carboplatin Metastatic Breast Cancer
US Oncology Research
Phase 2 Completed
NCT00370552 2016-03-10
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
R-Pharm
Phase 2 Completed
NCT00383149 2016-03-10
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
R-Pharm
Phase 2 Completed
NCT00490646 2016-03-10
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00546364 2016-03-10
IXTEND
R-Pharm
Phase 2 Terminated
NCT00593827 2016-03-10
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00633464 2016-03-10
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00455533 2016-02-24
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT01057212 2015-09-07
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Providence Health & Services
Phase 2 Terminated
NCT00022542 2015-04-15
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00821886 2014-12-22
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00751868 2014-12-17
GIM9
Consorzio Oncotech
Phase 2 Completed
NCT00331643 2014-11-14
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079326 2014-06-02
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00058019 2014-05-23
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077376 2014-05-21
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00023946 2014-05-14
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00087139 2014-05-09
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00022477 2013-09-05
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer
University of Chicago
Phase 2 Completed
NCT00033306 2013-08-05
BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
University of Alabama at Birmingham
Phase 2 Terminated
NCT00016393 2013-06-24
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016965 2013-06-24
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00052572 2013-06-24
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
National Cancer Institute (NCI)
Phase 2 Completed